Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: Strong association of IRS1 G972R variant and cancer risk

Prostate

Volumn 64, Issue 2, 2005, Pages 168-174

  Neuhausen, Susan L ^a,d   Slattery, Martha L ^b   Garner, Chad P ^a   Ding, Yuan C ^a   Hoffman, Michael ^b   Brothman, Arthur R ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

IGF1; INS; Insulin receptor substrate 1; IRS1; IRS2; Prostate cancer

Indexed keywords

INSULIN; SOMATOMEDIN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DNA POLYMORPHISM; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HUMAN; IGF1 GENE; INS GENE; IRS1 GENE; IRS2 GENE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; CASE-CONTROL STUDIES; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 20344390516     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20216     Document Type: Article

References (36)

1. ACS. Cancer Facts and Figures. Atlanta: American Cancer Society; 2004.
2. Li L, Yu H, Schumacher F, Casey G, Witte JS. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 2003;14(8):721-726.
3. Oliver SE, Gunnell D, Donovan J, Peters TJ, Persad R, Gillatt D, Pearce A, Neal DE, Hamdy FC, Holly J. Screen-detected prostate cancer and the insulin-like growth factor axis: Results of a population-based case-control study. Int J Cancer 2004;108(6): 887-892.
4. Stattin P, Stenman UH, Riboli E, Hallmans G, Kaaks R. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection. J Clin Endocrinol Metab 2001;86(12): 5745-5748.
5. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279(5350):563-566.
6. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998;90(12):911-915.
7. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94(14):1099-1106.
8. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: Implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83(7):2286-2290.
9. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003;107(6):873-877.
10. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 2002;63(4):317-332.
11. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 2000;19(49):5574-5581.
12. Baserga R. Insulin-like growth factor I receptor signalling in prostate cancer cells. Growth Horm IGF Res 2000;10(Suppl A):S43-S44.
13. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 1996;97(11):2569-2575.
14. He W, Craparo A, Zhu Y, O'Neill TJ, Wang LM, Pierce JH, Gustafson TA. Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2. J Biol Chem 1996;271(20):11641-11645.
15. Mammarella S, Romano F, Di Valerio A, Creati B, Esposito DL, Palmirotta R, Capani F, Vitullo P, Volpe G, Battista P, Della Loggia F, Mariani-Costantini R, Cama A. Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes. Hum Mol Genet 2000;9(17):2517-2521.
16. Crave JC, Lejeune H, Brebant C, Baret C, Pugeat M. Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells. J Clin Endocrinol Metab 1995;80(4):1283-1289.
17. Plymate SR, Jones RE, Matej LA, Friedl KE. Regulation of sex hormone binding globulin (SHBG) production in Hep G2 cells by insulin. Steroids 1988;52(4):339-340.
18. Hsing AW, Chua S Jr., Gao YT, Gentzschein E, Chang L, Deng J, Stanczyk FZ. Prostate cancer risk and serum levels of insulin and leptin: A population-based study. J Natl Cancer Inst 2001; 93(10):783-789.
19. Ho GY, Melman A, Liu SM, Li M, Yu H, Negassa A, Burk RD, Hsing AW, Ghavamian R, Chua SC Jr. Polymorphism of the insulin gene is associated with increased prostate cancer risk. Br J Cancer 2003;88(2):263-269.
20. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 1993;342(8875):828-832.
21. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, Corfas G, White MF. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003;23(18): 7084-7092.
22. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet 1999;23(1): 32-40.
23. Withers DJ, White M. Perspective: The insulin signaling system - a common link in the pathogenesis of type 2 diabetes. Endocrinology 2000;141(6):1917- 1921.
24. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183(1):1-9.
25. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999;253(1):1-6.
26. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62(10): 2942-2950.
27. Kurek R, Tunn UW, Eckart O, Aumuller G, Wong J, Renneberg H. The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 2000;85(1):125-129.
28. Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Burfeind P. Blockade of the type IIGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. J Pathol 2004;202(1):50-59.
29. Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK, Morrione A, Tu X, Baserga R. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 2000; 19(22):2687-2694.
30. Reiss K, Wang JY, Romano G, Tu X, Peruzzi F, Baserga R. Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells. Oncogene 2001;20(4):490-500.
31. Hribal ML, Federici M, Porzio O, Lauro D, Borboni P, Accili D, Lauro R, Sesti G. The Gly → Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab 2000;85(5):2004-2013.
32. Lee AV, Gooch JL, Oesterreich S, Guler RL, Yee D. Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3′-kinase inhibition. Mol Cell Biol 2000;20(5):1489-1496.
33. Vuori K, Ruoslahti E. Association of insulin receptor substrate-1 with integrins. Science 1994;266(5190):1576-1578.
34. Thomas DC, Clayton DG. Betting odds and genetic associations. J Natl Cancer Inst 2004;96(6):421-423.
35. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96(6):434-442.
36. Slattery ML, Samowitz W, Curtin K, Ma KN, Hoffman M, Caan B, Neuhausen S. Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev 2004;13(7):1206-1214.